EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Functional and behavioral outcomes in pediatric adrenal carcinoma under mitotane therapy: a caregiver-reported pilot study

Heidi Frey iD, Maria Riedmeier iD, Johanna Krüger, Carl Friedrich Classen, Nerea Domínguez-Pinilla, Maria Fragoso, Steffen Fuchs, Dominika Janus, Mouna Mezoued, Andrea Mocna, Jessica Munarin, Soraya Puglisi und 6 weitere

Endocrine Oncology · 01.01.2026 · 6 (1)

DOI: 10.1530/eo-26-0010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine Oncology, online erschienen am 15.05.2026. Verfasst von Heidi Frey und 17 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Würzburg, Department of Pediatrics, Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Wuerz…. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Mitotane is the standard therapy for advanced pediatric adrenocortical carcinoma (pACC). With improving survival, treatment-related long-term side effects and their impact on everyday functioning are becoming increasingly relevant. This multicenter pilot study provides first insights into this underexplored topic and lays the groundwork for future prospective investigations. Design and methods Caregivers of children with pACC treated with mitotane completed an online questionnaire. Based on these retrospective caregiver-reported data, treatment-related side effects and growth parameters were assessed. Using two validated instruments – Child and Adolescent Scale of Participation (CASP) and Strengths and Difficulties Questionnaire (SDQ) – caregivers rated functional participation and behavioral outcomes. We classified patients according to ongoing versus completed mitotane therapy and compared them with a sibling control group.

Results

The cohort included 24 children with pACC from eight countries, predominantly with advanced tumors (stage III–IV: 66.7%, median age: 7.4 years, 41.7% females). Half had completed mitotane therapy, and half were still receiving it. Most patients experienced relevant side effects, with adrenal insufficiency being the most frequent ongoing limitation. Patients on ongoing mitotane therapy showed reduced functional participation and more pronounced behavioral difficulties, whereas those who had completed therapy had outcomes comparable to their siblings.

Conclusion

The findings of this pilot study suggest temporary impairments in functional participation and psychosocial behavior during mitotane treatment, with improvement after therapy completion. In contrast, endocrine sequelae, particularly adrenal insufficiency, may persist beyond treatment. These observations underscore the need for standardized long-term endocrine follow-up and support the feasibility of larger, prospective studies to evaluate long-term neuropsychological outcome, especially in younger children.

Schlagwörter

Stichwörter der Autor:innen

adverse side effectsmitotaneneuropsychological long-term outcomepediatric adrenocortical carcinomapediatric adrenocortical tumor

Autor:innen und Institutionen

  • University Hospital Würzburg, Department of Pediatrics, Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Wuerzburg, Wuerzburg, Germany.
  • Pediatric Hematology and Oncology, Goethe-University Frankfurt, Frankfurt, Germany.
  • Division of Pediatric Oncology, Hematology and Palliative Medicine Section, Department of Pediatrics and Adolescent Medicine, University Medicine Rostock, Rostock, Germany.
  • Pediatric Hematology and Oncology Unit, University Hospital 12 de Octubre, I+12 Research Institute, Madrid, Spain.
  • Department of Pediatrics, University of São Paulo, São Paulo, Brazil.
  • Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

ORCID-Profile: Heidi Frey, Maria Riedmeier

Zitieren

APA

Frey, H., Riedmeier, M., Krüger, J., Classen, C. F., Domínguez-Pinilla, N., Fragoso, M., Fuchs, S., Janus, D., Mezoued, M., Mocna, A., Munarin, J., Puglisi, S., Susam Sen, H., Tuli, G., Walenciak, J., Yalcin, B., Fassnacht, M., & Wiegering, V. (2026). Functional and behavioral outcomes in pediatric adrenal carcinoma under mitotane therapy: a caregiver-reported pilot study. Endocrine Oncology, 6(1). https://doi.org/10.1530/eo-26-0010

Vancouver

Frey H, Riedmeier M, Krüger J, Classen CF, Domínguez-Pinilla N, Fragoso M, et al. Functional and behavioral outcomes in pediatric adrenal carcinoma under mitotane therapy: a caregiver-reported pilot study. Endocrine Oncology. 2026;6(1). doi:10.1530/eo-26-0010

BibTeX
@article{Frey2026,
  author = {Frey, Heidi and Riedmeier, Maria and Krüger, Johanna and Classen, Carl Friedrich and Domínguez-Pinilla, Nerea and Fragoso, Maria and Fuchs, Steffen and Janus, Dominika and Mezoued, Mouna and Mocna, Andrea and Munarin, Jessica and Puglisi, Soraya and Susam Sen, Hilal and Tuli, Gerdi and Walenciak, Justyna and Yalcin, Bilgehan and Fassnacht, Martin and Wiegering, Verena},
  title = {Functional and behavioral outcomes in pediatric adrenal carcinoma under mitotane therapy: a caregiver-reported pilot study},
  journal = {Endocrine Oncology},
  year = {2026},
  volume = {6},
  number = {1},
  doi = {10.1530/eo-26-0010}
}
Kostenlos starten →